Eagle Pharmaceuticals announced a change in management. Effective immediately Scott Tarriff, Founder, President, and CEO of the Company, has announced his resignation and retirement from his positions with the Company as President, CEO and Director on the Company’s Board of Directors. Michael Graves, Eagle Pharmaceuticals’ Chairman of the Board, has assumed the role of Interim Executive Chairman of the Board to lead the management team through this transition. The Company will institute a CEO search for Mr. Tarriff’s successor.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EGRX:
- Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q
- Eagle Pharmaceuticals Announces Management Change
- Eagle Pharmaceuticals is delaying the release of its Q3 results
- Eagle Delays Third Quarter 2023 Results and Conference Call
- Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023
